Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Elevated Plasma Levels of Mt4-Mmp and Mt6-Mmp; a New Observation in Patients With Thyroid Nodules Publisher Pubmed



Shirazkeytabar K1 ; Razavi SA2, 3 ; Abooshahab R2, 4 ; Salehipour P5 ; Akbarzadeh M2 ; Soroush A1 ; Hedayati M2 ; Nasiri S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Surgery, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Research and Development (R&D), Saeed Pathobiology & Genetics Laboratory, Tehran, Iran
  4. 4. Curtin Medical School, Curtin University, Bentley, 6102, Australia
  5. 5. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Archives of Iranian Medicine Published:2023


Abstract

Background: Based on the critical role of MT4-MMP and MT6-MMP in carcinogenesis, we focused on MT4-MMP and MT6-MMP circulating levels in patients with thyroid nodules. Methods: Plasma samples were collected from three groups, including papillary thyroid cancer (PTC; n = 30), multinodular goiter (MNG; n = 30), and healthy subjects (n = 22). Enzyme-linked immunosorbent assay (ELISA) was used to obtain the concentration of MT4-MMP and MT6-MMP in the three groups. Results: Analysis of data demonstrated increased levels of MT4-MMP (PTC: 4.90 ± 1.35, MNG: 4.89 ± 1.37, and healthy: 3.13 ± 1.42) and MT6-MMP (PTC: 8.29 ± 2.50, MNG: 7.34 ± 2.09, and healthy:5.01 ± 2.13) in thyroid nodules by comparison with healthy subjects (P< 0.05). There were no significant differences in the levels of the two MT-MMPs between PTC and MNG (P> 0.05). Increased plasma levels of MT4-MMP (odds ratio = 2.48; 95% CI: 1.46–4.19; P= 0.001) or MT6-MMP (odds ratio = 1.81; 95% CI: 1.29–2.53; P= 0.001) were associated with increased risk of PTC tumorigenesis. Interestingly, a strong positive association was observed between MT4-MMP and MT6-MMP in the three groups (PTC: r = 0.766**, P= 0.000; MNG: r = 0.856**, P= 0.000; healthy r = 0.947**, P= 0.000). Areas under the ROC curve for MT4-MMP and MT6-MMP were 0.82 and 0.96, respectively. At the cutoff value > 4.7 (ng/mL), MT4-MMP and MT6-MMP showed a sensitivity of 63.3% and 90.0%, respectively, with 100% specificity. Conclusion: Our work has led us to imply that the higher levels of MT4-MMP and MT6-MMP are closely linked with both PTC and MNG tumorigenesis. They may probably promote the development of thyroid lesions; however, more research is needed to further clarify the current findings. 2023 The Author(s).
Related Docs
1. Low Level of Plasma Fibulin-1 in Patients With Thyroid Lesions: A Case-Control Study and Literature Review, Molecular Biology Reports (2020)
2. Micro-Rnas As Critical Regulators of Matrix Metalloproteinases in Cancer, Journal of Cellular Biochemistry (2018)
3. Circulating Levels of Pten and Klln in Papillary Thyroid Carcinoma: Can They Be Considered As Novel Diagnostic Biomarkers?, Endocrine (2017)
Experts (# of related papers)
View all Related Experts
Mohammad Hossein Modarressi (1)
kazem Ahmadikia (1)